The role of antimetabolites in filtration surgery for neovascular glaucoma: intermediate-term follow-up

PURPOSE: To compare the intermediate-term efficacy of 5-fluorouracil (5-FU) and Mitomycin C (MMC) as adjunctive antimetabolites in neovascular glaucoma (NVG) filtration surgery. METHODS: Forty consecutive eyes of 40 patients with NVG refractory to medical therapy were randomized to receive antimetabolite-augmented trabeculectomy. Eighteen eyes received postoperative 5-FU (5-FU group) and 22 eyes received intraoperative, low-dose (0.2 mg/ml) MMC for 2 mins (MMC group). The main outcome measure was intraocular pressure (IOP). Surgical success was defined as IOP < 21 mmHg with topical treatment (qualified success) or without topical treatment (complete success). Surgical failure was defined as IOP > or = 21 mmHg, despite postoperative topical treatment, and by postoperative blindness. RESULTS: The mean follow-up period was 35.8 +/- 22.6 months in the 5-FU group and 18.6 +/- 17.2 months in the MMC group. This difference was not significant. Mean IOP decreased from 40.4 +/- 10.3 mmHg to 14.7 +/- 3.4 mmHg (p < 0.0001) in the 5-FU group and from 42 +/- 11.3 mmHg to 22.9 +/- 13.3 mmHg (p = 0.0006) in the MMC group; however, the difference between the 5-FU and MMC groups was not significant at any point. The success rate in the 5-FU group was 55.5% (44.4% complete, 11.1% qualified), compared with 54.5% (9.1% complete, 45.4% qualified) in the MMC group. This difference was not significant. CONCLUSIONS: The percentage of patients who achieved postoperative IOP < 21 mmHg was similar in both groups, although a larger proportion of patients treated with MMC-augmented trabeculectomy required topical treatment in comparison with the 5-FU group.     

Primary trabeculectomy with mitomycin C: safety and efficacy at 2 years

Purpose: To examine the rates of intermediate‐term intraocular pressure (IOP) control after trabeculectomy with adjunctive mitomycin C (MMC) and assess for associated complications. Methods: Medical records of patients undergoing primary trabeculectomy with MMC at Concord Repatriation Hospital, Sydney between January 1997 and December 2005 were reviewed. All eyes with a minimum of 2‐year follow up were included. Follow‐up data were collected in a standardized form on postoperative IOP, bleb‐related and other complications. Success was measured as IOP ≤ 18 mmHg and ≥6 mmHg (criteria 1) with (qualified success) or without (absolute success) the use of glaucoma medications. A secondary outcome measure was an IOP reduction of greater than 20% from baseline (criteria 2). Eyes with preoperative IOP of 18 mmHg or less were included, but also analysed separately to those eyes with preoperative IOP above 18 mmHg. Results: Sixty eyes from 42 patients were included in the study, with 3‐year follow up on 48 eyes. Mean preoperative IOP was 25.3 mmHg (range 8–45) and mean postoperative IOP was 14.0 mmHg at 1‐ and 2‐year follow up, and 14.7 mmHg at 3 years (ranges: 3–31, 4–30 and 8–45 mmHg respectively). Cumulative success for criteria 1 was 85.0% at 2 years and 83.3% at 3 years, and for criteria 2 it was 80.0% and 79.2%, respectively. The number of eyes on glaucoma medications was reduced from 51 preoperatively to 30 at 3 years. Complications were infrequent. There was one eye with a shallow anterior chamber beyond the immediate postoperative period. One eye required cataract surgery at 1‐year follow up. Subgroup analysis was performed using the first operated eye only, and results did not differ significantly from overall results. Conclusion: MMC‐augmented trabeculectomy can significantly reduce IOP in the short and intermediate term, with a favourable safety profile.     

Trabeculectomy with or without mitomycin-C for paediatric glaucoma in aphakia and pseudophakia following congenital cataract surgery

PURPOSE: To evaluate the safety and efficacy of trabeculectomy with or without mitomycin-C (MMC) in the management of glaucoma in aphakia and pseudophakia following congenital cataract surgery. PATIENTS AND METHODS: All patients of glaucoma with aphakia or pseudophakia who underwent trabeculectomy with or without MMC from January 1989 to April 2000 were included. The medical records of 19 consecutive patients (23 eyes) were reviewed. Data collected from a retrospective chart review were analysed. Outcome measures were evaluated using Kaplan-Meier survival analysis. Pre- and postoperative intraocular pressures (IOPs), visual acuities, success rate, bleb characteristics, surgical failure and complications were the main outcome measures. Successful IOP control was defined as an IOP between 6 and 21 mmHg, without antiglaucoma medications, without further antiglaucoma surgery and without any sight-threatening complication. RESULTS: The mean age of patients was 8.8+/-5.5 years at the time of trabeculectomy with MMC compared to 11.0+/-12.4 years for trabeculectomy without MMC. Eight patients underwent trabeculectomy with MMC and 11 patients underwent trabeculectomy without MMC. There was no statistically significant difference between the two groups in terms of visual acuity, IOP, antiglaucoma medications, age at cataract surgery and at trabeculectomy. The IOP reduced from a preoperative level of 34.2+/-8.9 mmHg (range: 20-52) to a postoperative level of 18.4+/-12.2 mmHg (range: 2-60) with a mean follow-up of 24.2+/-17.9 months. The mean reduction in IOP in the MMC group was 15.5+/-17.3 and 16.3+/-13.8 mmHg in the other group (P = 0.967). Overall, complete success was achieved in 36.8%, qualified success in 21.1% and surgical failure in 42.1% of patients with a mean follow-up of 24.2+/-17.9 months. There was no difference in the success between the two groups at the last follow-up. One patient developed bleb-related endophthalmitis in both eyes following trabeculectomy with MMC. CONCLUSIONS: The success rate of trabeculectomy in glaucoma following congenital cataract surgery was 36.8% at the end of 3 years. The present study proves a poor success rate of trabeculectomy in a small series of aphakic Asian Indian patients even with the use of MMC.     

丝裂霉素C联合粘小管成形术治疗开角型青光眼的疗效

目的:评估丝裂霉素C(MMC)联合粘小管成形术治疗开角型青光眼的效果.方法:回顾性研究.收集2007-12/2014-03接受粘小管成形术患者104例122眼.记录术前术后眼内压(IOP),青光眼用药数量,视力,并发症,辅助治疗(激光前房角穿刺或青光眼用药)和成功率.IOP≤21 mmHg无额外用药为完全成功,IOP≤21 mmHg有或无青光眼用药为部分成功.结果:术前平均IOP为27.5±9.2 mmHg,术后平均IOP为14.5±6.6 mmHg(P<0.001).术前平均视力为0.42±0.4,术后为0.32±0.4 (P=0.726).部分成功106眼(86.9%),完全成功62眼(50.8%).激光前房角穿刺术43眼(35.2%),青光眼药物使用率为49.1%.术后平均随访27.29±16.78 (1~79)mo.结论:粘小管成形术并发症发生率低且术后视力稳定,是一种安全的选择,术后补充进行激光前房角穿刺术可以提高手术成功率.丝裂霉素C对于粘小管成形术的作用还需进行深入的比较研究.     

Postoperative 5-fluorouracil versus intraoperative mitomycin C in high-risk glaucoma filtering surgery: extended follow up

Purpose: To compare the long‐term efficacy and safety of postoperative subconjunctival 5‐fluorouracil (5‐FU) injections with that of intraoperative mitomycin C (MMC) in eyes at high risk for failure of trabeculectomy. Methods: In a retrospective, non‐randomized comparative trial, 36 eyes of 36 consecutive patients at high risk for failure of trabeculectomy underwent glaucoma filtering surgery with either postoperative subconjunctival 5‐FU injections (19 eyes) or intraoperative application of MMC (17 eyes). Intraocular pressure, number of postoperative antiglaucoma medications, postoperative visual acuity, interventions, and complications were evaluated. Results: Overall success (intraocular pressure ≤21 mmHg) at 1 year was 73.6% in the 5‐FU group and 82.3% in the MMC group. The cumulative 4‐year success was 52.6% in the 5‐FU group and 60.5% in the MMC group (P = 0.6). At 4‐year follow up, mean ± SD intraocular pressures were 17.58 ± 4.01 mmHg in the 5‐FU group and 13.33 ± 3.36 mmHg in the MMC group (P = 0.01). There was no significant difference in the number of post­operative medications (P = 0.84), appearance of blebs (P = 0.20), final visual acuity (P = 1.00), and complications (P > 0.05) between the groups. Conclusions: These results suggest that both postoperative 5‐FU injections and intraoperative MMC application have long‐term success in high‐risk patients. However, MMC results in a greater decrease in intraocular pressure than 5‐FU.     

Efficacy and tolerability of nonpenetrating glaucoma surgery augmented with mitomycin C in treatment of open-angle glaucoma: a meta-analysis

Objective: To evaluate the efficacy and tolerability of nonpenetrating glaucoma surgery (NPGS) augmented with mitomycin C (MMC) compared with trabeculectomy (TE) plus MMC in the treatment of patients with open-angle glaucoma.Design: Systematic review and meta-analysis.Participants: Eight clinical trials, including 4 cohort and 4 randomized, enrolled 459 eyes.Methods: Pertinent studies were selected through extensive searches of the Cochrane Library, MEDLINE, EMBASE, and meeting abstracts. Efficacy measures were weighted mean differences (WMDs) for the percentage intraocular pressure (IOP) reduction and relative risks (RRs) for success rates. Tolerability measures were RRs for adverse events. Pooled estimates were carried out in RevMan software v. 4.2.Results: NPGS augmented with MMC was associated with a numerically smaller but nonsignificant percentage reduction in IOP compared with TE plus MMC, with a WMD of −1.27% (95% Cl −5.61 to 3.07) at 1 year, −4.55% (−10.35 to 1.24) at 2 years, −0.82% (−8.80 to 7.17) at 3 years, and −6.16% (−25.97 to 13.65) at 4 years. Significantly greater proportions of TE plus MMC patients than NPGS augmented with MMC patients achieved the target IOP without antiglaucoma medication at the end point, with a pooled RR of 0.74 (0.63-0.86). NPGS augmented with MMC was associated with a significantly lower frequency of shallow anterior chamber and cataract than TE plus MMC, with pooled RRs of 0.31 (0.16-0.60) and 0.23 (0.11-0.47), respectively.Conclusions: NPGS augmented with MMC was associated with IOP-lowering efficacy comparable to that of TE plus MMC. However, significantly fewer patients achieved the target IOP with NPGS augmented with MMC than with TE plus MMC. NPGS augmented with MMC was better tolerated than TE plus MMC.     

Trabeculectomy with brief exposure to mitomycin C

BACKGROUND: To evaluate the safety and efficacy of primary trabeculectomy with brief exposure (15 s) to mitomycin C (MMC) (0.4 mg/mL). METHODS: Medical record review of all patients who underwent primary trabeculectomy with brief exposure to MMC at the Goldschleger Eye Institute in a 4-year period was performed. RESULTS: Sixty-three patients (35 men, mean age of 55 years) underwent trabeculectomy with brief exposure to MMC. Intraocular pressure (IOP) decreased a mean +/- standard deviation of 17.9 +/- 9.6 mmHg from 30.4 +/- 9.5 mmHg preoperatively to 12.5 +/- 6.2 mmHg postoperatively after a mean follow up of 18.3 months (P < 0.001). Number of antiglaucoma medications decreased from 2.9 +/- 1.1 preoperatively to 0.2 +/- 0.4 postoperatively (P < 0.001, paired samples t-test). Complete success, defined as IOP < 18 mmHg without antiglaucoma medication, was achieved in 46 patients (73%) and qualified success, defined as IOP 相似文献   

Mid-term outcome of trabeculectomy with adjunctive mitomycin C in glaucoma patients

PurposeTo quantify the 2-year success rate and complications of trabeculectomy with adjunctive mitomycin C (MMC).MethodsA retrospective chart review was undertaken of 147 eyes that had undergone trabeculectomy with adjunctive MMC (concentration from 0.1 to 0.27 mg/mL) and at least 2 years' follow-up between January 2001 and March 2010. Demographic and clinical data were collected from all patients at the time of surgery and subsequent follow-up visits. Complete success was defined as intraocular pressure (IOP) ≤ 21 mmHg without any additional medication, whereas qualified success was defined as IOP ≤21 mmHg with or without medication.ResultsAt 24 months, mean IOP was 16.4 ± 10.6 mmHg, with a mean IOP decrease of 19.8 ± 14.2 mmHg. In primary glaucoma patients (n = 66), 60.6% and 95.4% of eyes achieved complete success and qualified success, respectively, at 2-year follow-up. Sub-group analysis of the initial trabeculectomy in primary glaucoma patients (n = 49) showed that complete and qualified success increased to 65.3% and 98.0%, respectively. The success rate was lower in secondary glaucoma patients (n = 74), with complete success at 41.9% and qualified success at 67.6% at 2-year follow-up. Eighty-six eyes (58.5%) developed one or more complications, from mild, such as hyphema, to severe, such as bleb leakage, which could necessitate surgical intervention. Twenty-six eyes developed severe complications, such as wound gap after 5 postoperative days, hypotony, hypotony maculopathy, choroidal detachment, overhanging bleb, bleb leakage, and endophthalmitis. A comparison between eyes with severe complications and other eyes in relation to different MMC amount, defined as MMC concentration multiplied by application duration, revealed no significant difference (p = 0.136). Further glaucoma surgery was performed in 27 eyes (18.4%).ConclusionThe outcome of trabeculectomy with low-dose intraoperative MMC is favorable in primary glaucoma patients at 2-year follow-up. Severe complications are not significantly related to MMC amount. Factors associated with severe complications require further study. Careful selection of MMC concentration and application time based on preoperative and intraoperative risk factors may further improve surgical results.     

微导管辅助的小梁切开术治疗原发性先天性青光眼的远期疗效观察

目标评估微导管辅助小梁切开术治疗原发性先天性青光眼的远期效果和安全性。设计回顾性病例系列。研究对象2014年2月至2016年12月北京同仁眼科中心微导管辅助小梁切开术治疗的原发性先天性青光眼患者65例(86眼),手术时年龄2个月~11岁,平均(3.7±2.8)岁。方法术后3、6、9个月以及1、2、3、4、5、6年进行随访。比较术前、术后末次随访时(或手术失败时)眼压及降眼压药物使用数量的变化。术后不使用降眼压药物,且眼压≤21 mmHg为绝对成功;术后需使用降眼压药物控制眼压≤21 mmHg为条件成功。主要指标眼压、抗青光眼药物使用数量、术中及术后并发症,远期手术干预。结果平均随访(46.3±9.9)个月(36~72个月)。35眼为初次手术,51眼具有抗青光眼手术史。术前平均眼压(32.5±6.4)mmHg,平均应用(2.8±0.6)种药物;末次随访平均眼压(15.6±7.9)mmHg,平均用药(0.4±1.0)种,二者较术前均显著下降(P均<0.001)。术后1、3、5年累积绝对成功率分别为90.7%、86.0%、68.8%,累积条件成功率分别为90.7%、88.3%、76.9%。随访至术后5年,累积绝对成功率既往无手术史者(94.3%)比有手术史者(60.2%)高(P=0.04)。无严重手术并发症发生。结论微导管辅助的小梁切开术治疗原发性先天性青光眼长期安全有效。抗青光眼手术史会影响远期手术成功率。     

Adjunctive mitomycin C in primary trabeculectomy in young adults: a long-term study of case-matched young patients

· Objective: The purpose of this study was to determine the efficacy of initial mitomycin C (MMC)-augmented trabeculectomy for uncomplicated glaucoma in young patients. · Methods: A retrospective chart review was performed on all glaucoma patients aged between 15 and 40 years without previous surgery that underwent initial trabeculectomy with MMC between 1988 and 1995 at the University Eye Hospital of Cologne. Success (survival) was defined as an intraocular pressure (IOP) of 21 mmHg or lower, with (qualified success) or without (complete success) glaucoma medications. The results were compared with a case-matched control group that did not receive antiproliferative therapy. · Results: Eleven eyes of 11 patients fulfilled the inclusion criteria of initial MMC-augmented trabeculectomy. Using cumulative life-table analysis the success rate was 91% at 1 year and 73% at 5 years for the control group. For the MMC group the success rate was 91% at 1 year and 5 years, respectively. At final visit, mean IOP was significantly (P<0.001) lower for the MMC group (13.3±3.9 mmHg) than for controls (18.0±1.3 mmHg). Significant differences were also found in the complication rate: complications associated with excessive aqueous overfiltration, such as shallow anterior chamber (36%), choroidal detachment (45%) and persistent hypotony (27%), featured particularly in the MMC group. Conversely, scarring of the filtering bleb (18%) and Tenon’s cysts (18%) were observed exclusively in control eyes. · Conclusion: The present results suggest that initial MMC trabeculectomy for uncomplicated glaucoma in young patients significantly reduces IOP and number of adjunctive medications, postoperatively, albeit at the price of a high incidence of hypotony. Received: 24 November 1997 Revised version received: 19 January 1998 Accepted: 27 January 1998     

Outcome of trabeculectomy with intraoperative mitomycin C for uveitic glaucoma

BACKGROUND: The purpose of this study was to compare the outcomes of mitomycin C (MMC)-augmented trabeculectomy in glaucoma patients with uveitis to those without uveitis but with other high-risk characteristics. METHODS: A retrospective comparative cohort analysis consisting of 51 eyes of 51 patients (21 uveitic patients and 30 nonuveitic patients) was performed. Two outcome classifications were analyzed: absolute success (intraocular pressure [IOP]相似文献   

Deep sclerectomy with mitomycin C in failed trabeculectomy

AIM: To evaluate the success rate and complications associated with deep sclerectomy with mitomycin C (MMC) and a reticulated hyaluronic acid implant in previously failed trabeculectomy. METHODS: This prospective study included 20 eyes with a previously failed trabeculectomy, which were treated with deep sclerectomy with 0.2 mg/ml MMC application under the conjunctiva and superficial scleral flap. Intraocular pressure (IOP), glaucoma medications, visual acuity, and complications were recorded preoperatively and 1 day, 1 week, and 1, 3, 6, and 12 months postoperatively. RESULTS: The mean preoperative IOP was 25.8+/-7.3 mmHg; the IOP significantly decreased to 14.6+/-3.2 mmHg 1 year postoperative. At each interval, the mean IOP was significantly lower than preoperatively (P=0.000). At 1 year, the complete success rate (IOP相似文献   

The effect of adjustable suture (Khaw) trabeculectomy on intraocular pressure: a retrospective case series

The aim of the study is to investigate long-term intraocular pressure (IOP) outcome as well as complications associated with adjustable suture trabeculectomy in glaucoma patients who were uncontrolled under maximum medical therapy. In this retrospective case series, 35 eyes of 30 patients are included in the study. Adjustable suture trabeculectomy with 0.2 mg/cc mitomycin-C for 3 min was performed by the same surgeon. Subconjunctival 5-fluorouracil injection, transconjunctival suture adjustment, digital massage, and/or argon suturolysis were utilized postoperatively as needed. Complete success, qualified success, and failure were defined as IOP ≤18 mmHg without medication, IOP ≤18 mmHg with one or more medications, and IOP >18 mmHg with medication or need for additional glaucoma surgery, respectively. Of the 35 eyes, 13 had primary open angle, 18 had psuedoexfoliative, 1 had juvenile, 1 had pigmentary, 1 had uveitic, and 1 had chronic angle-closure glaucoma. Mean preoperative IOP of 30.1 ± 10.5 mmHg dropped to 10.8 ± 4.7 mmHg (p < 0.001) after a mean follow-up of 595 ± 435 days. Nine eyes had the desired IOP on first postoperative day where no transconjunctival suture adjustment was performed. Remaining 26 eyes required a mean of two adjustments (range 1–7) during the first postoperative 24 days in order to achieve a desirable IOP. Complete success, qualified success, and failure were observed in 28 (80 %), 5 (14 %), and 2 (6 %) eyes, respectively. There were no serious complications related to adjustable suture trabeculectomy. We believe adjustable suture trabeculectomy to be a safe and effective alternative to standard trabeculectomy where a desirable low IOP can be achieved.     

复合式小梁切除术联合醛化脐带静脉管植入治疗难治性青光眼

目的:评价醛化脐带静脉管(human umbilical vein,HUV)在复合式小梁切除术中治疗难治性青光眼的临床疗效。方法:具有高危因素如新生血管、葡萄膜炎、无晶状体、人工晶状体和发育性的难治性青光眼28例28眼。15例行复合式小梁切除术联合巩膜瓣下HUV植入,13例行复合式小梁切除术。术后观察、比较的指标包括:手术成功率、术后眼内压(intraocular pressure,IOP)、抗青光眼药物使用数量以及术后并发症。所有研究对象随访12mo。结果:术后6mo,手术完全成功:HUV组12/15(80.0%),对照组8/13(61.5%);术后12mo,手术完全成功:HUV组11/15(73.3%),对照组6/13(46.2%)。术后12mo,HUV组和对照组IOP分别从术前50.9±12.2,49.7±11.7mmHg降至17.3±1.1,20.9±2.2mmHg(P=0.00)。由于滤过过强,对照组术后早期出现低眼压2例,HUV组无低眼压;对照组出现包裹性滤过泡4例,HUV组仅出现1例。结论:复合式小梁切除术联合HUV治疗难治性青光眼与复合式小梁切除术相比,具有手术成功率高,术后IOP控制良好、平稳,术后并发症发生率低的特点。     

房角手术治疗小儿无晶状体眼青光眼

目的:探讨小梁切开术和房角切开术治疗小儿无晶状体眼青光眼的效果。方法:选择1997/2010年接受先天性白内障手术后进而因无晶状体眼青光眼接受小梁切开术和房角切开术的患儿。手术治疗成功的标准是术后眼压≤24mmHg,无论是否需要局部药物的辅助使用,且避免了小梁切除术或引流阀植入,在随访期间没有明显并发症。排除标准:眼前段发育不全、小角膜、白内障手术时即发生的青光眼、随访<1a。结果:符合纳入标准10例12眼。其中,2眼仅行房角切开术,2眼房角切开术后进而接受了小梁切开术,8眼仅行小梁切开术。房角手术前平均眼压为35±10mmHg,末次随访的平均眼压为22±4mmHg(P=0.0005)。12眼中有7眼获得了成功(58%):5眼(42%)是在单一的小梁切开术后获取成功的,2眼(17%)在接受房角切开术后进而于术后7mo和15mo时接受了引流阀植入。结论:小梁切开术和房角切开术治疗小儿无晶状体眼青光眼的效果满意。     

外伤性房角退缩性青光眼小梁切除联合丝裂霉素治疗

目的观察小梁切除术术中联合应用丝裂霉素C（Mitomycin C，MMC）治疗外伤性房角退缩性青光眼的效果。方法小梁切除术联合术中心用MMC治疗外伤性房角退缩性青光眼22例（22眼）。术后对眼压、视力和并发症进行了分析。以Kaplan—Meier寿命表判断成功率。结果成功标准为：不用或用局部抗青光眼药物，眼压在6～21mmHg之间；不需要再进行抗青光眼手术；并且未发生严重的并发症。6月累积成功率为86．36％（n=22），12月为78．57％（n=14），18月为66．67％（n=6）。术后视力与术的相间或稍有提高17例（77．27％），视力下降5例（22．73％）。并发症包括浅前房6眼、溥壁滤过泡3眼、低眼压1眼和白内障1眼。结论小梁切除术联合MMC是治疗外伤性房角退缩性青光眼一种有效的方法。术后大部分病人眼压被控制，保存了有用的视力。     

Long-term outcome of trabeculectomy in terms of intraocular pressure

PURPOSE: To evaluate the outcome, long-term results and contributing prognostic factors of trabeculectomy in terms of intraocular pressure (IOP) and to compare the results in primary open-angle glaucoma (POAG) and exfoliation glaucoma (EG). METHODS: This study involved retrospective evaluation of 138 consecutive patients (138 eyes) with either POAG or EG. All patients had undergone primary trabeculectomy performed by the same surgeon between November 1994 and August 1996. Only one eye per patient was included. Operations performed with the use of antimetabolites were excluded. All patients were aged over 40 years and were white. Follow-up for all subjects lasted at least 2 years. Successful control of IOP was defined as achieving IOP < or = 21 mmHg without medication (complete success) or with a single topical medication (qualified success). Success rates were determined using the Kaplan-Meier survival curve, and risk factors were analysed with proportional hazards regression. RESULTS: According to the Kaplan-Meier survival curve, success rates (complete or qualified) were 82% at 1 year, 70% at 2 years, 64% at 3 years and 52% at 4 years. A total of 63% were complete successes at 1 year, 54% at 2 years, 45% at 3 years and 40% at 4 years. Complete success rates were significantly better in the POAG group than in the EG group. Proportional hazards regression analysis showed that the presence of EG and early postoperative IOP > 30 mmHg decreased the possibility of complete success, while a cataract operation performed during follow-up improved it. CONCLUSION: The IOP-reducing effect of trabeculectomy decreases gradually. After 4 years, 52% of operated eyes had IOP < or = 21 mmHg with or without a single topical medication. Diagnosis of EG implied a worse long-term outcome for trabeculectomy in terms of IOP.     

ReGAE 7: long-term outcomes of augmented trabeculectomy with mitomycin C in African Caribbean patients

Background: To evaluate long‐term outcomes and complication rates following trabeculectomy with mitomycin C in a case series of African Caribbean patients. Design: A prospective, observational and non‐comparative case series. Participants: Forty‐seven consecutive African Caribbean patients (47 eyes) with glaucoma. Methods: All patients underwent augmented trabeculectomy with mitomycin C for uncontrolled intraocular pressure (IOP). Survival analysis was performed with a minimum of 12 months' follow up. Main Outcome Measures: Surgical success was based upon IOP reduction to ≤21 mmHg, ≤18 mmHg and ≤15 mmHg without glaucoma medication (complete); or IOP reduction to ≤21 mmHg, ≤18 mmHg and ≤15 mmHg with or without glaucoma medication (qualified). Results: The mean follow‐up period was 48.6 months. At 3 years post‐trabeculectomy 92.6% achieved a qualified success and 59.3% a complete success for an IOP ≤21 mmHg. At final follow up the mean IOP reduced from 33.7 mmHg to 13.1 mmHg (P < 0.0001). Survival rates were 96%, 90% and 86% at 12, 24 and 36 months, respectively, with a mean survival time of 97.4 months (95% confidence interval, 86.0–108.8) for an IOP ≤21 mmHg. Early postoperative hypotony requiring surgical intervention occurred in four (8.5%) patients. There were no cases of blebitis, endophthalmitis, suprachoroidal haemorrhage, malignant glaucoma or hypotony maculopathy. Conclusions: Good long‐term stable IOP can be achieved with low complication rates and high success rates amongst African Caribbean patients following trabeculectomy with mitomycin C. A proactive postoperative management regime is needed to ensure trabeculectomy survival in high‐risk populations.     

改良黏弹剂Schlemm管切开术治疗青少年型青光眼的临床研究

目的:观察改良的黏弹剂Schlemm管切开术治疗青少年型青光眼的疗效及安全性.方法:对被诊断为青少年型青光眼的27例43眼患者施行改良的黏弹剂Schlemm管切开术.记录患者的性别、接受该手术治疗时的年龄、是否有青光眼家族史、术前术后最佳矫正视力、青光眼药物使用情况、眼压及其它手术情况.记录具体手术步骤及术中术后是否发生明显的并发症.结果:改良的黏弹剂Schlemm管切开术治疗青少年型青光眼,术后2a的成功率为74%,术前平均眼压为35.38±7 15mmHg.2a后,患者平均眼压16.50±2.52mmHg,眼压下降值为18.88mmHg(P<0.01).术中及术后均未出现明显并发症.结论:长期随访的数据显示改良的黏弹剂Schlemm管切开术治疗青少年型青光眼有较好的临床效果,结合其术中、术后的并发症较少等优点,该手术有望成为青少年型青光眼的首选治疗术式.     

A comparative study of trabeculectomy and the new clear‐cornea filtering procedure,intrastromal diathermal keratostomy (IDK)

Purpose: For the first time to compare the 1‐year success rates of trabeculectomy and the new clear‐cornea filtering procedure, intrastromal diathermal keratostomy (IDK). Methods: Prospective clinical observational study including 99 consecutively operated eyes (69 patients) with well‐established primary open‐angle glaucoma referred for filtering operation. We compared the change in intraocular pressure (IOP), number of anti‐glaucomatous medication, complications and reoperations after 1 year. Seventy‐four eyes were operated with trabeculectomy, and 25 with IDK. Complete success was defined as IOP ≤18 mmHg, IOP lowered ≥30%, no medication and no reoperation. Qualified success was defined as IOP ≤18 mmHg, and IOP lowered ≥30% with or without medication or reoperation. Results: Intraocular pressure pre‐ and postoperatively in the trabeculectomy group was 25.3 and 14.1 mmHg versus 23.8 and 15.8 mmHg in the IDK group. The number of medications pre‐ and postoperatively in the trabeculectomy group was 3.1 and 0.5 versus 3.2 and 1.3 in the IDK group. Forty‐four (59%) of the eyes in the trabeculectomy group met the complete success criteria compared with 5 (20%) in the IDK group (p < 0.01). Sixty‐eight (92%) in the trabeculectomy group and 16 (64%) in the IDK fulfilled the qualified success criteria (p < 0.01). Conclusion: Both the complete and qualified 1‐year success rates of IDK are significantly lower compared with the success rates of trabeculectomy. The IDK does not reduce the IOP as much as the procedure of trabeculectomy, and it carries a higher frequency of reoperations and more medication postoperatively. Thus, our prospective data do not support the procedure of IDK as ‘the gold standard’ for filtering surgery in patients with open‐angle glaucoma.